EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Statins to reduce renal sinus fat among breast cancer patients undergoing anthracycline-based chemotherapy: A substudy of PREVENT-WF-98213

William W Hundley, Nathaniel S O'Connell, Danielle L Kirkman, Kristine C Olson iD, Kerryn W Reding, Bonnie Ky, Kathryn J Ruddy, Glenn J Lesser, Ralph B D'Agostino, W Gregory Hundley, Moriah P Bellissimo iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0318017 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von William W Hundley und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia…. Hauptthemen laut MEDLINE: Adipose Tissue, Anthracyclines, Atorvastatin, Breast Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To test if statin administration attenuated renal sinus fat (RSF) accumulation and if RSF was associated with renal function in women with breast cancer (BC) receiving anthracycline-based chemotherapy.

Methods

This was a secondary analysis in a subgroup of women with stage I-III BC randomized to placebo (n = 35) or statin (40 mg/day atorvastatin, n = 44) therapy. At baseline and 24-months after randomization, RSF and intraabdominal fat were measured from magnetic resonance images, and estimated glomerular filtration rate (eGFR) was calculated from serum creatinine.

Results

Participants in this study averaged 51 years of age (SD 11), 87% reported White race, and had a mean BMI (±SD) of 30.2 kg/m 2 (±6.1). Most participants (60%) were diagnosed with stage II BC. At 24-months, RSF was higher in the placebo group relative to the statin group (β [95% CI], p-value: 0.17 [0.009, 0.34], p = 0.04). After adjusting for baseline RSF, this signal remained but was attenuated (β [95% CI], p-value: 0.12 [−0.06, 0.29], p = 0.18). In all participants at baseline and prior to beginning chemotherapy for BC or study drug, higher RSF was associated with lower eGFR values in all participants (r = −0.23, p = 0.03). At 24-months by study group, greater RSF was associated with decreased eGFR in the placebo group (−0.51, p = 0.01) but not in the statin group (−0.25, p = 0.19).

Discussion

Statin administration may lower RSF during anthracycline-based chemotherapy. These findings merit further investigation to determine if statins protect renal function during BC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adipose TissueAnthracyclinesAtorvastatinBreast NeoplasmsHydroxymethylglutaryl-CoA Reductase InhibitorsAdultAgedFemaleHumansMiddle AgedGlomerular Filtration RateKidneySecondary Data Analysis

Substanzen

AnthracyclinesAtorvastatinHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Cardiology, Pauley Heart Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia, United States of America.
  • Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America.
  • Department of Kinesiology and Health Sciences, Virginia Commonwealth University, Richmond, Virginia, United States of America.
  • Department of Biobehavioral Nursing and Health Informatics, University of Washington School of Nursing, Seattle, Washington, United States of America.
  • Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
  • Department of Oncology, Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota , United States of America.

ORCID-Profile: Kristine C Olson, Moriah P Bellissimo

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute
  • National Institutes of Health
  • Susan G. Komen
  • American Heart Association

Zitieren

APA

Hundley, W. W., O'Connell, N. S., Kirkman, D. L., Olson, K. C., Reding, K. W., Ky, B., Ruddy, K. J., Lesser, G. J., D'Agostino, R. B., Hundley, W. G., & Bellissimo, M. P. (2025). Statins to reduce renal sinus fat among breast cancer patients undergoing anthracycline-based chemotherapy: A substudy of PREVENT-WF-98213. PLOS One. https://doi.org/10.1371/journal.pone.0318017

Vancouver

Hundley WW, O'Connell NS, Kirkman DL, Olson KC, Reding KW, Ky B, et al. Statins to reduce renal sinus fat among breast cancer patients undergoing anthracycline-based chemotherapy: A substudy of PREVENT-WF-98213. PLOS One. 2025. doi:10.1371/journal.pone.0318017

BibTeX
@article{Hundley2025,
  author = {Hundley, William W and O'Connell, Nathaniel S and Kirkman, Danielle L and Olson, Kristine C and Reding, Kerryn W and Ky, Bonnie and Ruddy, Kathryn J and Lesser, Glenn J and D'Agostino, Ralph B and Hundley, W Gregory and Bellissimo, Moriah P},
  title = {Statins to reduce renal sinus fat among breast cancer patients undergoing anthracycline-based chemotherapy: A substudy of PREVENT-WF-98213},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0318017}
}
Kostenlos starten →